Nasdaq

Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds

VANCOUVER, BC / ACCESSWIRE / July 21, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned ...
WATE 6 On Your Side

Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy

VANCOUVER, BC / ACCESSWIRE / May 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiaries ...
KRQE Blogs

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current ...

VANCOUVER, BC / ACCESSWIRE / December 1, 2023 / Core One Labs Inc. ("Core One" or the "Company") (CNSX:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU), an emerging leader in the field of neuroscience ...
Nasdaq

Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of ...

VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that ...
Emily Standley Allard on MSN

Psychedelic therapy’s surprising journey from taboo to mainstream medicine

Psychedelic therapy, involving substances like psilocybin (found in magic mushrooms), MDMA, and ketamine, is gaining recognition as a groundbreaking approach to treating mental health conditions, ...